Garcia E, Camps-Renom P, Puig N et al. J Transl Med. 2023 Feb 19;21(1):131. doi: 10.1186/s12967-022-03867-w. PMID: 36805772
Abstract:
Background 18F-fuorodeoxyglucose positron emission tomography (18F-FDG PET) identifes carotid plaque infam‑ mation and predicts stroke recurrence. Aim Our aim was to evaluate the performance of soluble low-density lipoprotein receptor-related protein 1 (sLRP1) as an indicator of carotid plaque infammation.
Methods A prospective study was conducted among adult patients with recent (<7 days) anterior circulation ischemic stroke and at least one atherosclerotic plaque in the ipsilateral internal carotid artery. Patients under‑ went an early (<15 days from inclusion) 18F-FDG PET, and the maximum standardized uptake value (SUVmax) within the plaque was measured. sLRP1 levels were measured in plasma samples by ELISA. The association of sLRP1 with SUVmax was assessed using bivariate and multivariable linear regression analyses. Hazard ratios (HR) were esti‑ mated with Cox regression to evaluate the association between circulating sLRP1 and stroke recurrence.
Results The study was conducted with 64 participants, of which 57.8% had ≥50% carotid stenosis. The multivari‑ able linear and logistic regression analyses showed that sLRP1 was independently associated with (i) SUVmax within the plaque (β=0.159, 95% CI 0.062–0.257, p=0.002) and (ii) a probability of presenting SUVmax ≥2.85 g/mL (OR=1.31, 95% CI 1.00–1.01, p=0.046), respectively. Participants with stroke recur
Funding: The economic support to develop this project was received from Fundació La Marato TV3 (201716.10), from the Instituto de Salud Carlos III (co-fnanced by the European Regional Development funds, FEDER), FIS PI15/00884 (to JM-F), FIS PI19/00421 (to PC-R and SB) and FIS PI21/01523 (to VLl-C), from Fundación BBVA Ayudas a equipos de investigación 2019 (“Translational Molecular Imaging for Detection of Cholesterol Entrapment in the Vasculature with 68 Ga-labeled LRP1-derived Peptides” to VLl-C), from Sociedad Española de Arteriosclerosis Grant 2021 (to SB), and from Acadèmia de Ciències Mèdiques de Catalunya I Balears Grant (to DV). The team is part of CIBER of Diabetes and Metabolic Diseases (CIBERDEM, CB07/08/0016 to SB and JLS-Q) and CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to DV and VLl-C) run by the Instituto de Salud Carlos III. AB-A. (FI19/00205) and NP (FI20/00252) are predoctoral fellows granted by the Programme_Contratos predoctorales de formación de investigación en salud_ from the Instituto de Salud Carlos III (ISCIII) and co-fnanced with ERDFs. EG, AB-A and VLl-C are members of Redes de investigación (Enfermedades Metabólicas y Cáncer RED2018-102799-T), a project run by MINECO. VLl-C, AB-A and DV are members of the Quality Research Group 2017 SGR 946 and SB, NP and JLS-Q of the 2017-SGR-1149 group from the Generalitat de Catalunya. SB, PC-R, JM-F and AA-S are mem‑ bers of RICORS-ICTUS (RD21/0006/0006), and FEDER. VLL-C, EG, NP; SB and JLS-Q are members of the Spanish Atherosclerosis Society Vascular Biology Group. IR-SANTPAU is a centre of CERCA Programme/Generalitat de Catalunya.